cMet Rabbit Polyclonal Antibody (ER40501)

UNIPROT #

P08581

PROTEIN NAME

cMet

SYNONYMS

AUTS9 antibody;c met antibody;D249 antibody;Hepatocyte growth factor receptor antibody;HGF antibody;HGF receptor antibody;HGF/SF receptor antibody;HGFR antibody;MET antibody;Met proto oncogene tyrosine kinase antibody;MET proto oncogene, receptor tyrosine kinase antibody;Met proto-oncogene (hepatocyte growth factor receptor) antibody;Met proto-oncogene antibody;Met protooncogene antibody;MET_HUMAN antibody;Oncogene MET antibody;Par4 antibody;Proto-oncogene c-Met antibody;RCCP2 antibody;Scatter factor receptor antibody;SF receptor antibody;Tyrosine-protein kinase Met antibody

SEQUENCE SIMILARITIES

Belongs to the protein kinase superfamily. Tyr protein kinase family.

DEVELOPMENTAL STAGE

Low though detectable expression at 10 dpc. From 15 dpc at least until 17 dpc, expression strongly increases. Down-regulated in the adult.

POST-TRANSLATIONAL MODIFICATION

Autophosphorylated in response to ligand binding on Tyr-1232 and Tyr-1233 in the kinase domain leading to further phosphorylation of Tyr-1347 and Tyr-1354 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1347 and Tyr-1363 (By similarity). Dephosphorylated by PTPN1 and PTPN2 (By similarity).; Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors.; (Microbial infection) Tyrosine phosphorylation is stimulated by L.monocytogenes InlB.

SUBCELLULAR LOCATION

Secreted, membrane.

FUNCTION

c-Met (MET or MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR). MET is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, MET induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain.